Advanced search
Publication Cover
Substance Abuse and Rehabilitation Volume 13, 2022 - Issue
Submit an article Journal homepage
219
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Services Available at United States Addiction Treatment Facilities That Offer Medications versus Behavioral Treatment Only: A Cross-Sectional, Observational Analysis

Andrea Weber1 Department of Psychiatry, University of Iowa Health Care, Iowa City, IA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7124-776X
ORCID Icon,
Benjamin Miskle1 Department of Psychiatry, University of Iowa Health Care, Iowa City, IA, USA
,
Alison Lynch1 Department of Psychiatry, University of Iowa Health Care, Iowa City, IA, USA
,
Stephan Arndt1 Department of Psychiatry, University of Iowa Health Care, Iowa City, IA, USA;2 Department of Biostatistics, University of Iowa, Iowa City, IA, USA
&
Laura Acion3 Universidad de Buenos Aires – CONICET, Instituto de Cálculo, Ciudad Autónoma de Buenos Aires, ArgentinaORCID Iconhttps://orcid.org/0000-0001-5213-6012
ORCID Icon
Pages 57-64 | Received 17 Jan 2022, Accepted 19 Aug 2022, Published online: 07 Sep 2022

References

  • SAMHSA. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH series H-55). Available from: https://www.samhsa.gov/data/. Accessed August 20, 2022.
  • Overdose deaths accelerating during Covid-19; 2020. Available from: cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html. Accessed March 12, 2021.
  • Ainscough TS, McNeill A, Strang J, Calder R, Brose LS. Contingency management interventions for non-prescribed drug use during treatment for opiate addiction: a systematic review and meta-analysis. Drug Alcohol Depend. 2017;178:318–339. doi:10.1016/j.drugalcdep.2017.05.028
  • Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93–103. doi:10.1097/ADM.0000000000000193
  • Rees CE, Cleland JA, Dennis A, Kelly N, Mattick K, Monrouxe LV. Supervised learning events in the foundation programme: a UK-wide narrative interview study. BMJ Open. 2014;4(10):e005980. doi:10.1136/bmjopen-2014-005980
  • Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–157. doi:10.1176/appi.ps.201300235
  • Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019;114(8):1396–1404. doi:10.1111/add.14620
  • Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550
  • Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683–1694. doi:10.1111/add.14991
  • SAMHSA. Finding quality treatment for substance use disorders; 2018. Available from: store.samhsa.gov/product/Finding-Quality-Treatment-for-Substance-Use-Disorders/PEP18-TREATMENT-LOC. Accessed August 20, 2022.
  • NIAAA. Step 1 - search trusted sources to find providers. Available from: alcoholtreatment.niaaa.nih.gov/how-to-find-alcohol-treatment/step-1-search-trusted-sources-to-find-providers#search-programs. Accessed March 12, 2021.
  • Mark TL, Dowd WN, Council CL. Tracking the quality of addiction treatment over time and across States: Using the federal government’s “Signs” of higher quality. tracking the quality of addiction treatment over time and across states: using the federal government’s “Signs” of higher quality. RTI Press Research Report Series. 2020.
  • Abraham AJ, Andrews CM, Harris SJ, Friedmann PD. Availability of medications for the treatment of alcohol and opioid use disorder in the USA. Neurotherapeutics. 2020;17(1):55–69. doi:10.1007/s13311-019-00814-4
  • Marynak K, VanFrank B, Tetlow S, et al. Tobacco cessation interventions and smoke-free policies in mental health and substance abuse treatment facilities - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(18):519–523. doi:10.15585/mmwr.mm6718a3
  • Substance Abuse and Mental Health Services Administration. Data from: treatment episode data set admissions (TEDS-A): 2017. 2019.
  • Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
  • US surgeon general’s advisory on naloxone and opioids overdose; 2020. Available from: https://www.hhs.gov/surgeongeneral/priorities/opioids-and-addiction/naloxone-advisory/index.html. Accessed March 10, 2020.
  • Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Admission practices and cost of care for opioid use disorder at residential addiction treatment programs in the US. Health Aff. 2021;40(2):317–325. doi:10.1377/hlthaff.2020.00378
  • Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108–112. doi:10.1111/jrh.12307
  • Marino R, Perrone J, Nelson LS, et al. ACMT position statement: remove the waiver requirement for prescribing buprenorphine for opioid use disorder. J Med Toxicol. 2019;15(4):307–309. doi:10.1007/s13181-019-00728-9

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.